Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
Lu D, Li C, Riggs M, Polhamus D, French J, Agarwal P, Chen SC, Vadhavkar S, Patre M, Strasak A, Quartino A, Jin JY, Girish S. Lu D, et al. Among authors: polhamus d. Cancer Chemother Pharmacol. 2019 Jul;84(1):175-185. doi: 10.1007/s00280-019-03852-z. Epub 2019 May 17. Cancer Chemother Pharmacol. 2019. PMID: 31102024 Clinical Trial.
Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
Chen SC, Quartino A, Polhamus D, Riggs M, French J, Wang X, Vadhavkar S, Smitt M, Hoersch S, Strasak A, Jin JY, Girish S, Li C. Chen SC, et al. Among authors: polhamus d. Br J Clin Pharmacol. 2017 Dec;83(12):2767-2777. doi: 10.1111/bcp.13381. Epub 2017 Sep 3. Br J Clin Pharmacol. 2017. PMID: 28733983 Free PMC article. Clinical Trial.
Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
Li C, Wang B, Chen SC, Wada R, Lu D, Wang X, Polhamus D, French J, Vadhavkar S, Strasak A, Smitt M, Joshi A, Samant M, Quartino A, Jin J, Girish S. Li C, et al. Among authors: polhamus d. Cancer Chemother Pharmacol. 2017 Dec;80(6):1079-1090. doi: 10.1007/s00280-017-3440-4. Epub 2017 Oct 11. Cancer Chemother Pharmacol. 2017. PMID: 29022084 Clinical Trial.
Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor.
Yin O, Zahir H, French J, Polhamus D, Wang X, van de Sande M, Tap WD, Gelderblom H, Wagner AJ, Healey JH, Greenberg J, Shuster D, Stacchiotti S. Yin O, et al. Among authors: polhamus d. CPT Pharmacometrics Syst Pharmacol. 2021 Nov;10(11):1422-1432. doi: 10.1002/psp4.12712. Epub 2021 Oct 14. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34585528 Free PMC article.
Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia.
Galluppi GR, Polhamus DG, Fisher JM, Hopkins SC, Koblan KS. Galluppi GR, et al. Among authors: polhamus dg. CPT Pharmacometrics Syst Pharmacol. 2021 Oct;10(10):1245-1254. doi: 10.1002/psp4.12692. Epub 2021 Aug 10. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34292664 Free PMC article.
A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects.
Tsukada H, Chen YL, Xiao G, Lennek L, Milanovic SM, Worden M, Polhamus DG, Chiu YY, Hopkins SC, Galluppi GR. Tsukada H, et al. Among authors: polhamus dg. Clin Pharmacokinet. 2023 Dec;62(12):1755-1763. doi: 10.1007/s40262-023-01317-4. Epub 2023 Oct 26. Clin Pharmacokinet. 2023. PMID: 37882999 Free PMC article.
14 results